Therachon

Pfizer Acquires Clinical-Stage Biotech Therachon

Expands Pfizer’s rare disease portfolio with potential first-in-class therapy for achondroplasia, a genetic condition and the most common form... Read More
Therachon

Therachon Receives EMA and FDA Orphan Drug Designation for TA-46 for Achondroplasia

BASEL, Switzerland — June 20, 2017 – Therachon AG, a biotechnology company focused on rare genetic diseases, announced today that... Read More